OR WAIT null SECS
Facility will house 44,000 square feet of clinical and commercial cGMP, and other tech services
Thermo Fisher Scientific Inc., a contract development and manufacturing organization (CDMO), and the University of California, San Francisco (UCSF) have partnered up to form a strategic alliance, as they look to speed up the development and manufacturing of cell-based therapies.
With an anticipated completion date of 2022, Thermo Fisher will be constructing and operating a 44,000-square-foot cell therapy development, manufacturing and collaboration center in leased space on UCSF's Mission Bay campus, which also features biomedical research facilities and hospitals. The site will offer clinical and commercial cGMP (current good manufacturing practice) cell therapy manufacturing services, along with associated technology development support, to UCSF and other partners.
The space will also serve as a hub for customers and UCSF researchers to be able to access Thermo Fisher's Cell Therapy Systems (CTS) reagents, consumables and fit-for-purpose instrumentation and compliant software. The CTS product portfolio is intended to work in tandem with, and provide a transition from research to clinical manufacturing, to addressing cell therapy production workflow tasks.